On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
- Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
- Development of Japan-Made Vaccines “Significantly Meaningful”: Minister
April 12, 2021
- MSD’s Recarbrio Up for PAFSC Review on April 21
April 8, 2021
- Label Update Will Suffice to Expand COVID-19 Vaccination Age: MHLW Official
April 7, 2021
- AMED to Set Up Council to Hone Academic Seeds with Industry Input
April 7, 2021
- MHLW Launches New Office to Fuel SaMD Commercialization
April 6, 2021
- MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
April 6, 2021
- Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
- Japan Mulls Expanding COVID-19 Vaccination Age to 12-15
April 5, 2021
- MHLW Calls for Thiola’s Priority Use for Cystinuria as Shortage Expected
April 2, 2021
- Neurosurgical Expert Eager to Carry Out Bridging Study of Cannabis-Derived Drug in Japan
April 2, 2021
- Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
April 1, 2021
- Japan to Research Duration of COVID-19 Vaccine Efficacy: Minister
March 31, 2021
- Label Revisions Ordered for Utemerin and More Drugs, 1st Update for Zolgensma
March 31, 2021
- 1.35% of Tokyo Residents Have Coronavirus Antibodies: MHLW
March 31, 2021
- Govt’s Drug Development Panel Adopts 5 Priority Topics for Discussion
March 31, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…